12/3
04:33 pm
rani
Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/24
04:05 pm
rani
Rani Therapeutics to Participate in the Evercore Healthcare Conference
Medium
Report
Rani Therapeutics to Participate in the Evercore Healthcare Conference
11/21
02:05 pm
rani
Rani Therapeutics (NASDAQ:RANI) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Rani Therapeutics (NASDAQ:RANI) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
05:51 pm
rani
Osteoporosis Market Set to Expand Significantly During the Forecast Period (2025-2034) Due to Rising Aging Population and Novel Therapeutics | DelveInsight [Yahoo! Finance]
Medium
Report
Osteoporosis Market Set to Expand Significantly During the Forecast Period (2025-2034) Due to Rising Aging Population and Novel Therapeutics | DelveInsight [Yahoo! Finance]
11/6
04:30 pm
rani
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
Medium
Report
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
10/31
01:05 pm
rani
Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
High
Report
Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/30
08:00 am
rani
Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025
High
Report
Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025
10/26
06:31 am
rani
H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill Potential [Yahoo! Finance]
Medium
Report
H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill Potential [Yahoo! Finance]
10/23
04:05 pm
rani
Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors
High
Report
Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors
10/23
04:01 pm
rani
Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
High
Report
Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
10/21
08:05 am
rani
Rani Therapeutics (NASDAQ:RANI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
High
Report
Rani Therapeutics (NASDAQ:RANI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
10/20
01:29 pm
rani
Rani Therapeutics (NASDAQ:RANI) had its price target raised by analysts at Maxim Group from $5.00 to $10.00. They now have a "buy" rating on the stock.
High
Report
Rani Therapeutics (NASDAQ:RANI) had its price target raised by analysts at Maxim Group from $5.00 to $10.00. They now have a "buy" rating on the stock.
10/19
11:50 pm
rani
Rani Therapeutics (RANI): Examining Valuation After Landmark Chugai Deal and $60M Funding Boost [Yahoo! Finance]
High
Report
Rani Therapeutics (RANI): Examining Valuation After Landmark Chugai Deal and $60M Funding Boost [Yahoo! Finance]
10/18
02:28 pm
rani
Rani Therapeutics (RANI) Is Up 257.9% After $1.08 Billion Chugai Deal and $60M Fundraise—What's Changed [Yahoo! Finance]
High
Report
Rani Therapeutics (RANI) Is Up 257.9% After $1.08 Billion Chugai Deal and $60M Fundraise—What's Changed [Yahoo! Finance]